Eli Lilly’s diabetes drug faces more shortages as demand kicks up
Higher doses of Lilly’s popular diabetes drug, Mounjaro, are now being impacted by shortages as demand has kept high.
By Madison Muller and Nacha Cattan, Bloomberg
Shortages of Eli Lilly & Co.’s Mounjaro have expanded to include all of the higher doses, showing just how strong demand is for the drug before it even gets formal approval for use in obesity.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Weight loss drug shortage now includes Saxenda
For subscribers
